Avacta Group PLC Avacta's CSO to Present at Major US Conference
June 12 2019 - 2:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
12 June 2019
12 June 2019
Avacta Group plc
("Avacta", the "Company" or the "Group")
Avacta's Chief Scientific Officer to Present at Major US
Conference
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents, is pleased to announce that its Chief
Scientific Officer, Dr Amrik Basran, will be presenting at the Next
Generation Protein Therapeutics & Bioconjugates conference in
San Francisco, California on 19 June 2019.
Dr Basran's presentation, 'Affimer Therapeutics: A Novel Human
Scaffold for the Generation of Bi-specific Molecules', will give an
overview of the benefits of using Affimer technology to generate
bispecific drug molecules.
Bispecific therapy - single molecules that engage with two drug
targets simultaneously - is a major area of focus in large pharma
immuno-oncology programmes. Avacta has highlighted bispecifics as a
key element of its therapeutic pipeline strategy, alongside the
development of its novel tumour microenvironment activated drug
conjugates.
Dr Basran's presentation will highlight the stability,
solubility and ease of manufacturing functional Affimer bispecifics
incorporating Avacta's proprietary serum half-life extension
technology (Affimer XT(TM) ), as well as PD-L1 and LAG-3 Affimer
inhibitors.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial
Officer
finnCap Ltd (Nominated Adviser Tel: +44 (0) 207 220 0500
and Joint Broker) www.finncap.com
Geoff Nash / Giles Rolls - Corporate
Finance
Tim Redfern - ECM Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
WG Partners (Joint Broker) www.wgpartners.co.uk
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Turner Pope Investments Tel: +44 (0) 203 621 4120
James Pope / Ben Turner www.turnerpope.com
Yellow Jersey PR (Financial Media
and IR) Tel: +44 (0)7764 947 137
Sarah Hollins Tel: +44 (0)7544 275 882
Harriet Jackson avacta@yellowjerseypr.com
Zyme Communications (Trade and Tel: +44 (0)7787 502 947
Regional Media) katie.odgaard@zymecommunications.com
Katie Odgaard
About Avacta Group plc - www.avacta.com
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology as well as partnered development
programmes. Avacta is commercialising non-therapeutic Affimer
reagents through licensing to developers of life sciences research
tools and diagnostics.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKDDKPBKDOAD
(END) Dow Jones Newswires
June 12, 2019 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024